Advanced Neuroendocrine Carcinomas: Enfortumab-Vedotin Study

We are studying a new treatment for patients with advanced Neuroendocrine Carcinomas who cannot use standard chemotherapy. The goal is to see if this treatment can help shrink tumors and improve survival.

>2 years11-15 visitsEfficacy phase (II)No PlaceboStandard MedicinesInjectionEndocrinologyOncology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Padcev
Padcev is a cancer medicine used to treat advanced or metastatic bladder cancer in adults.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Enfortumab Vedotin
Enfortumab vedotin is a targeted cancer substance used to treat advanced or metastatic urothelial (bladder) cancer after prior therapies.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Hospital Universitari Vall D Hebron
Oncología Médica
Barcelona, Spain
MD Anderson Cancer Center
Oncología Médica
Chamartín, Spain
Hospital Universitario Ramon Y Cajal
Oncología Médica
Colmenar Viejo, Spain
Sponsor: Grupo Espanol De Tumores Neuroendocrinos
Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.